COVID-19 illness: Different comorbidities may require different immunological therapeutic targets

Area of Science:

• Immunology
• Infectious Diseases
• Critical Care Medicine

Background:

• The SARS-CoV-2 pandemic caused millions of deaths, with high mortality in Intensive Care Units (ICUs).
• Current treatments like antivirals and corticosteroids are less effective in patients with comorbidities (diabetes, hypertension, obesity, etc.).
• These comorbidities share distinct inflammatory pathways regulated by specific cytokines, impacting COVID-19 outcomes.

Purpose of the Study:

• To explore the biological basis of comorbidities influencing SARS-CoV-2 infection.
• To identify how distinct cytokine profiles associated with comorbidities can guide therapeutic strategies.
• To improve treatment outcomes for severe COVID-19 by addressing comorbidity-specific pathobiology.

Main Methods:

• Systematic literature review of PubMed.
• Analysis of studies on comorbidity biology and immunological treatments for COVID-19.
• Evaluation of cytokine signatures in relation to specific comorbidities.

Main Results:

• Hypertension and atrial fibrillation show an IL-6 dependent inflammatory signature.
• Diabetes, obesity, heart failure, and CNS diseases exhibit an IL-1a/b predominant signature.
• Targeting specific cytokines (IL-6 or IL-1a/b) or broader pathways (JAKs) may enhance treatment efficacy based on comorbidity profile.

Conclusions:

• Comorbidities significantly impact SARS-CoV-2 infection course through distinct inflammatory mechanisms.
• Personalized immune-modifying therapy, guided by cytokine profiles, is crucial for severe COVID-19.
• Further research into comorbidity-specific treatments can optimize patient outcomes.